Pravastatin and cognitive function in the elderly. Results of the PROSPER study
read more
Citations
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Vascular Contributions to Cognitive Impairment and Dementia A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Interpretation of the evidence for the efficacy and safety of statin therapy.
References
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Brain Infarction and the Clinical Expression of Alzheimer Disease: The Nun Study
Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.
Related Papers (5)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Frequently Asked Questions (10)
Q2. What is the effect of pravastatin on cognitive decline in late life?
Since high cholesterol levels in midlife are associated with accelerated cognitive decline in late-life, additional studies are necessary to study a possible beneficial effect of statin treatment in midlife on cognitive decline in late-life.
Q3. What was the outcome parameter for the Stroop test?
The outcome parameter for the Stroop test was the total number of seconds required to complete the third Stroop card containing 40 items.
Q4. What was the purpose of the study?
ParticipantsPROSPER was a prospective multicentre randomized placebo-controlled trial to assess whether treatment with pravastatin diminishes the risk of major vascular events in elderly people.
Q5. What was the main outcome variable for the LDT?
The outcome variable for the LDT was the total number of correct entries completed in 60 s. Memory was assessed with the 15-Picture Learning test (PLT) which measures immediate and delayed recall.
Q6. What is the effect of pravastatin on cognitive function in old age?
All cognitive tests showed a significant decline over time, confirming their adequate sensitivity to pick up deterioration of cognitive function in old age.
Q7. Why did the authors use a linear mixed model for statistical analyses?
Linear mixed models for statistical analyses were used because this method handles repeated measurements within subjects accurately.
Q8. What is the main reason for the lack of cognitive benefit of statins in old age?
it might be that the association between cardiovascular disease and cognitive decline is primarily driven by clinical strokes, and statin treatment in PROSPER did not decrease the risk of stroke.
Q9. What was the main outcome variable for the pravastatin trial?
The main outcome variable for immediate recall was the accumulated number of pictures recalled over the three learning trials and for delayed recall the number of pictures recalled after 20 min.
Q10. What is the reason for the lack of prescription bias in the study?
Prescription bias might explain why cross-sectional studies and short follow-up studies found positive associations between statin use and cognitive function.